We are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers affecting patients with high unmet need, where there are limited or no treatment options. Since our inception in 2016, we have received clearance from the U.S. Food and Drug Administration, or the FDA, for three investigational new drug applications, or INDs, and successfully advanced these three programs into clinical development. In addition, we have three unique programs in various stages of preclinical development that we plan to advance into clinical development beginning in 2021.

Our lead product candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5, or PRMT5. The company is currently evaluating:

*its lead product candidate PRT543 in a Phase 1 trial with an initial focus in select solid tumors and myeloid malignancies, and

*its lead product candidate PRT811 in a Phase 1 clinical trial in solid tumors, including glioblastoma multiforme. (Glioblastoma multiforme is the most aggressive type of cancer that starts in the brain.)

Prelude is also initiating clinical trial activities for its lead product candidate PRT1419 in selected hematological malignancies.